The facility is led by EVGN member Marina Mione, IFOM scientist and leader of the Zebrafish group. Developed after an IFOM proposal to the consortium, the technological platform will provide EVGN members with the possibility to test and validate in this unique in vivo system data previously obtained in vitro. Funding comes from EVGN and it covers an initial period of 2 years (with 60.000€/yr). At present, there are 5 ongoing collaborative projects involving EVGN partner laboratories from Italy, Germany, Finland, U.K. and France, whose completion is expected in one or two years.
Zebrafish (Danio rerio) is an ideal low-cost powerful model widely used for screening the angiogenic and cardiovascular regenerative properties of novel genes, for the validation of new drugs and drug targets and for the investigation of other human diseases (neurodegenerative diseases, osteoarthritis etc.). This is not surprising, as this model organism is endowed with an immune system, and fully functional nervous and cardiovascular systems. Besides, many human genes have an equivalent in Zebrafish and a number of biochemical pathways are similar between fish and men, albeit the two species are distant.
Easy to grow, the individuals become sexually mature at three months and the females lay up to 300 eggs per mating. The most interesting feature, however, is represented by the eggs themselves, which are transparent and allow the direct observation of inner events. “For this reason – points out IFOM scientist Marina Mione - this system is particularly suitable to observe any experimental modification, especially those that involve the early steps of the vascular system’s development”.
Angiogenesis, the blood vessels growth that occurs during embryogenesis or after myocardial infarction and stroke, is a complex event. During its physiological course it is precisely modulated at the genetic level. However, there are times where it would be desirable to modulate this process at will: boosting it after an ischemic event that leaves tissues without oxygen, or dimming it in tumours that sprout their own vessels to nourish themselves. In both cases, Zebrafish proves to be the ideal model system for hypothesis testing and validation.
“The rapid life cycle of Zebrafish together with eggs’ transparency – confirms Marina Mione – are two of the most interesting features of this organism. They allow real time screening of any introduced modification and are especially useful when it comes to the analysis of the vascular development. Blood vessels growth starts early but Zebrafish needs functional vessels only after several days, since the embryo is vital even in the absence of a fully formed vascular system. This is a clear advantage over other experimental systems. We can monitor what happens whether blood vessels are defective, follow their anomalous growth and correlate any visible alteration to the mutation we introduced.”
Investigations carried out in Mione’s laboratory include the generation of transgenic Zebrafish to observe directly cell behaviour during vasculogenesis (de novo vessel formation) and angiogenesis (vessel sprouting), the suppression of a gene of interest (technically called knock-down) as well as the rescue of an original character. “Loss- and gain-of-function experiments are part of so-called reverse genetics”, says Mione. “They are easy to perform in Zebrafish and very informative, since they provide critical information for the study of candidate genes”. In gain-of-function experiments scientists ask what would happen if a specific gene is activated in the embryo where it is not normally active, whereas in loss-of-function experiments, they ask what happens when a particular function is removed from the embryo altogether.
The experiment design starts in one EVGN institution where initial data are gathered from in vitro systems; then Mione and colleagues carry out in vivo assays to confirm the hypotheses. Hence the collaborative effort between the partners helps to provide complete answers to asked questions. Among the projects that Mione is following, there is a study carried out in collaboration with the EVGN laboratory directed by Seppo Ylä-Herttuala, at the Department of Biotechnology and Molecular Medicine, A.I.Virtanen Institute, University of Kuopio, Finland. "We are studying vasculogenesis – says Kati Pulkkinen, who works in Seppo Ylä-Herttuala's laboratory in Kuopio – using a technique called knockdown morpholinos, to inactivate genes in a selective way. Our experiments are at an early stage. But results are coming, and we are in the middle of confirming them.
“Another important part of our research – says Mione – is the definition of the molecular mechanisms that govern angiogenesis during tumour growth, as well as the selection of antiangiogenic drugs”. To this purpose, fluorescence vascularization tests in Zebrafish are extremely useful because they allow to unveil the involvement of some genes in the angiogenesis of tumours, and to screen drugs potentially able to stop the process.
Angiogenesis, drug screening and drug targeting are some of the most important issues EVGN scientists are focussing on. This is why the newly established Zebrafish platform has been welcomed with much enthusiasm, as it is expected to give meaningful contribution to the understanding of the process and to suggest new strategies to modulate it at clinical level.
“Recent studies – observes Alain Tedgui, EVGN Scientific Coordinator from INSERM U689 in Paris - indicate that using Zebrafish we can investigate not only the molecular mechanisms of development, but also the cellular and molecular physiology and pathology in the adult. In the context of EVGN, cardiovascular pharmacology and angiogenesis are certainly the two areas in which we can expect fruitful findings. A potential limitation of this model system is that, so far, there is no report that atherosclerosis develops in Zebrafish vessels. However, it may be just a question of time to be able to do so!”
The European Vascular Genomics Network (EVGN) is a network of excellence funded by the European Commission under the 6th Framework Programme "Life Science, genomics and biotechnology for Health", aiming at integrating and strengthening the European research area in the field of Cardiovascular Diseases (Contract Number: LSHM-CT-2003-503254). Additional information on the EVGN is available at http://www.evgn.org/
Francesca Noceti | alfa
Multi-institutional collaboration uncovers how molecular machines assemble
02.12.2016 | Salk Institute
Fertilized egg cells trigger and monitor loss of sperm’s epigenetic memory
02.12.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.
Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy